Novo Nordisk AS

NVO

Company Profile

  • Business description

    With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

  • Contact

    Novo Alle 1
    Bagsvaerd2880
    DNK

    T: +45 44448888

    E: [email protected]

    https://www.novonordisk.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2024

    Employees

    72,000

Novo Nordisk AS News & Analysis

stocks

Obesity drug stocks: Why it will be ‘exceptionally difficult’ to dethrone Eli Lilly and Novo Nordisk

The two biggest players in the market appear poised to dominate for years to come.
stocks

Obesity drug stocks: Where to invest now

Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,633.1066.100.77%
CAC 407,255.0141.690.58%
DAX 4019,322.59176.420.92%
Dow JONES (US)44,296.51426.160.97%
FTSE 1008,262.08112.811.38%
HKSE19,229.97371.14-1.89%
NASDAQ19,003.6531.230.16%
Nikkei 22538,283.85257.680.68%
NZX 50 Index13,041.90276.662.17%
S&P 5005,969.3420.630.35%
S&P/ASX 2008,393.8070.800.85%
SSE Composite Index3,267.19103.21-3.06%

Market Movers